Combined monophosphoryl lipid A and alpha-Galactosyl ceramide adjuvants enhance the systemic immune response to intranasal inactivated influenza vaccination in a murine homologous challenge model

Inactivated influenza vaccines (IIVs) often fail to provide robust mucosal protection, necessitating the development of potent adjuvants for intranasal delivery. This study evaluated a novel adjuvant combination of Monophosphoryl lipid A (MPL), a TLR4 agonist, and alpha-Galactosyl Ceramide (α-GalCer), an NKT cell ligand, to enhance the efficacy of an intranasal inactivated A/PR8 (iPR8) influenza vaccine. In vitro results demonstrated that MPL+ α-GalCer increased the frequencies of CD4⁺ CD25⁺ , CD8⁺ CD25⁺ and CD4⁺ CD69⁺ T cells relative to both the vehicle control and either single adjuvant in splenocyte cultures, whereas in purified dendritic cell and macrophage cultures MPL+ α-GalCer was no more effective than MPL alone. Splenocyte supernatants showed higher elevated TNF- α, IL-2, IFN-γ, IL-4, and IL-13. This pre-activation drove robust allogeneic T-cell proliferation in a mixed lymphocyte reaction, indicating enhanced allostimulatory capacity rather than influenza-specific priming. In vivo , a single intranasal dose of iPR8+ MPL+ α-GalCer elicited high systemic IgG titers and was effective at inducing Th1-associated IgG2a alongside IgG1. Following an LD50-range PR8 challenge, the combined-adjuvant group showed 100% survival, which was not statistically significant and lower lung viral titers at 7 days post-infection. This group exhibited elevated post-challenge lung-associated antigen-specific IgA and a reduced viral burden, which was accompanied by lower inflammatory cell infiltration and cytokine levels. The protection of combination group was accompanied by increased frequencies of ex vivo antigen-responsive CD4 + and CD8 + T cells recovered post-challenge. Our findings suggest that the MPL+ α-GalCer combination enhances innate and adaptive immune responses, providing an effective adjuvant platform for homologous mucosal protection in a murine model.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-11
DOI
https://doi.org/10.1371/journal.pone.0362356
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Combined monophosphoryl lipid A and alpha-Galactosyl ceramide adjuvants enhance the systemic immune response to intranasal inactivated influenza vaccination in a murine homologous challenge model

Len Ho Thi, Eun‐Ju Ko, Thanh Tam Pham
PLoS ONE
Influenza Virus Research Studies
article

Combined monophosphoryl lipid A and alpha-Galactosyl ceramide adjuvants enhance the systemic immune response to intranasal inactivated influenza vaccination in a murine homologous challenge model

Len Ho Thi, Eun‐Ju Ko, Thanh Tam Pham
article en

Abstract

Inactivated influenza vaccines (IIVs) often fail to provide robust mucosal protection, necessitating the development of potent adjuvants for intranasal delivery. This study evaluated a novel adjuvant combination of Monophosphoryl lipid A (MPL), a TLR4 agonist, and alpha-Galactosyl Ceramide (α-GalCer), an NKT cell ligand, to enhance the efficacy of an intranasal inactivated A/PR8 (iPR8) influenza vaccine. In vitro results demonstrated that MPL+ α-GalCer increased the frequencies of CD4⁺ CD25⁺ , CD8⁺ CD25⁺ and CD4⁺ CD69⁺ T cells relative to both the vehicle control and either single adjuvant in splenocyte cultures, whereas in purified dendritic cell and macrophage cultures MPL+ α-GalCer was no more effective than MPL alone. Splenocyte supernatants showed higher elevated TNF- α, IL-2, IFN-γ, IL-4, and IL-13. This pre-activation drove robust allogeneic T-cell proliferation in a mixed lymphocyte reaction, indicating enhanced allostimulatory capacity rather than influenza-specific priming. In vivo , a single intranasal dose of iPR8+ MPL+ α-GalCer elicited high systemic IgG titers and was effective at inducing Th1-associated IgG2a alongside IgG1. Following an LD50-range PR8 challenge, the combined-adjuvant group showed 100% survival, which was not statistically significant and lower lung viral titers at 7 days post-infection. This group exhibited elevated post-challenge lung-associated antigen-specific IgA and a reduced viral burden, which was accompanied by lower inflammatory cell infiltration and cytokine levels. The protection of combination group was accompanied by increased frequencies of ex vivo antigen-responsive CD4 + and CD8 + T cells recovered post-challenge. Our findings suggest that the MPL+ α-GalCer combination enhances innate and adaptive immune responses, providing an effective adjuvant platform for homologous mucosal protection in a murine model.

PLoS ONEVol. 21(11)
Jeju National University (KR)
Influenza Virus Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Combined monophosphoryl lipid A and alpha-Galactosyl ceramide adjuvants enhance the systemic immune response to intranasal inactivated influenza vaccination in a murine homologous challenge model — Len Ho Thi, Eun‐Ju Ko, et al. · PLoS ONE (2026) | TGRS Research Map | TGRS